Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a water barrier make microwave ablation safer for the womb?

NCT ID NCT06751264

Disease control Sponsor: Peking University Aerospace Center Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial compares two microwave ablation techniques for treating uterine adenomyosis, a condition where uterine tissue grows into the muscle wall, causing pain and heavy bleeding. One group receives the standard approach with saline injected around the uterus, while the other adds an extra step of injecting ice-cold saline into the uterine cavity to protect the lining. The study aims to see if this added step reduces the risk of endometrial injury and improves symptom relief.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
microwave ablation with improved ultrasound guidance and water isolation
What this could lead to
If successful, this approach could make microwave ablation safer and more effective for treating adenomyosis, potentially preserving the uterine lining and reducing complications.
What could go wrong
This is an early-stage trial, and the added procedure may not significantly improve outcomes or could carry its own risks, such as injury to the endometrium or other complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 137 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. UFs or AM diagnosed by pathology and ultrasound； 2. Relevant symptoms such asabnormal uterine bleeding, secondary anemia, progressive dysmenorrhea and enlargement of the uterus； 3. Voluntarily undergo MWA； 4. a confirmed available safe transabdominal puncture path； Exclusion Criteria: 1. Pregnancy or malignancy； 2. Severe and uncorrectable coagulation disorders； 3. Severe cardiac, liver, and renal dysfunction； 4. Anesthesia allergy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adenomyosis of uterus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adenomyosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adenomyosis of uterus

Contacts and locations

Locations

  • Aerospace Center Hospital

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.